Tamala, Cherry L.

HRN: 09-41-01  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/22/2024
CEFUROXIME 500MG (TAB)
03/22/2024
03/29/2024
PO
500mg
BID X 7 Days
S/P NSVD With RMLE And Repair
Checking Final Appropriateness 

Indication:  ProphylaxisEmpiric    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: